Protease Inhibitors: Amprenavir
Contents Introduction Information card Pharmacokinetics Dosing Side effects Drug interactions

Introduction

The information represented on this drug does not necessarily correspond with the information that can be found in the Belgian scientific leaflet.
Amprenavir is an antiretroviral drug for treament of people with HIV disease. This drug has not been approved by the Food and Drug Administration and thus is not available by perscription. An expanded access program has begun as of december 1998.

Abbreviation(s):  Generic name: Brand name: APV amprenavir Agenerase®		USA (FDA) Adult approval date: Pediatric approval date: Not FDA approved, but in expanded access as of 12/98
Pharmaceutical co.: Glaxo Wellcome Inc.		Belgium: Not yet a price neither reimbusable.

Pharmacokinetics

Because of its long half-life (approximately 7 hours), amprenavir can be administered twice daily. Amprenavir is metabolized by cytochrome P450 CYP3A and therefor the drug can have complex effects on other therapies.(106)

Dosing

Eight 150-mg tablets must be given twice daily, with or without food. (106)

Side effects

In small studies, nausea, diarrhea, and headache were all reported, but were uncommon and typically mild. Rash, once thought to be common with amprenavir, can occur, but its incidence appears to be low. (106)

Drug interactions
 
 

Interactions with other antiretroviral agents

Click here